MIM
NAUT icon

MetLife Investment Management’s Nautilus Biotechnolgy NAUT Stock Holding History

MetLife Investment Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,613
Closed -$87.2K – 2840
2024
Q3 		$87.2K Buy
+30,613
New +$79.2K ﹤0.01% 2678
2024
Q1 		– Sell
-28,043
Closed -$83.8K – 2810
2023
Q4 		$83.8K Hold
28,043
– – ﹤0.01% 2676
2023
Q3 		$88.6K Hold
28,043
– – ﹤0.01% 2637
2023
Q2 		$109K Buy
+28,043
New +$80.8K ﹤0.01% 2624

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's NAUT Position: Q4 2024 in Review

MetLife Investment Management sold out of Nautilus Biotechnolgy (NAUT) in Q4 2024, closing a stake of 30,613 shares — an estimated $87.2K sold.

MetLife Investment Management first reported a position in NAUT in Q2 2023 and held it in 4 quarters. The position peaked at $109K in Q2 2023. 88 funds tracked by Wall St. Rank hold NAUT as of Q4 2024.

  • MetLife Investment Management reported no remaining Nautilus Biotechnolgy position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 30,613 Nautilus Biotechnolgy shares in Q4 2024, an estimated $87.2K.
  • MetLife Investment Management first reported a position in Nautilus Biotechnolgy in Q2 2023 and held it in 4 quarters.
  • MetLife Investment Management's Nautilus Biotechnolgy position peaked at $109K in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.